BackJW (Cayman) Therapeutics Ltd Overview

JW (Cayman) Therapeutics Ltd Current Assets

Track JW (Cayman) Therapeutics Ltd's current assets ($450M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$451.27M
↓ 39.59% YoYΔ $-295.77M vs prior year quarter

Peer trimmed avg / median

Loading

JW (Cayman) Therapeutics Ltd Current Assets History

Loading

JW (Cayman) Therapeutics Ltd vs. peers: Current Assets Comparison

Loading

JW (Cayman) Therapeutics Ltd Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

JW (Cayman) Therapeutics Ltd (JWCTF) FAQ

JW (Cayman) Therapeutics Ltd's current assets stands at $450M as of June 2026. That compares with $750M in the prior-year period — down 39.6% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

JW (Cayman) Therapeutics Ltd reported $450M in current assets versus $750M a year earlier — a 39.6% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $750M in the prior-year period — down 39.6% year over year. Sustained growth in current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how JW (Cayman) Therapeutics Ltd's current assets evolved across reporting periods, while the comparison chart places JWCTF next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current assets is commonly used to spot outliers. JW (Cayman) Therapeutics Ltd's reading of $450M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.